Candriam Equities L Biotechnology Class C USD CapRegistrer dig for at låse op for ratings |
Fondens performance | 31-03-2024 |
Vækst af 1.000 (DKK) | Avanceret graf |
Fond | 9,0 | 4,7 | 5,0 | 3,8 | 5,2 | |
+/-Kat | -9,8 | 7,7 | 17,7 | 2,5 | 1,4 | |
+/-Indeks | -16,4 | -2,2 | 8,0 | -6,4 | -4,8 | |
Kategori: Sektor - Bioteknologi, Aktier | ||||||
Kategoribenchmark: Morningstar Gbl Biotechnolo... |
Oversigt | ||
Seneste NAV 16-04-2024 | USD 794,79 | |
Kursændring 1 dag | -0,80% | |
Morningstar Kategori™ | Sektor - Bioteknologi, Aktier | |
ISIN | LU0108459040 | |
Markedsværdi i alt (mio.) 16-04-2024 | USD 1465,45 | |
Seneste TNA(mio.) 16-04-2024 | USD 324,13 | |
Emissionstillæg | 3,50% | |
Løbende omkostning 01-03-2024 | 1,98% | |
Investeringsstrategi | Aktiv |
Morningstar Research |
Analyst Report | 18-03-2024 Jeffrey Schumacher, Director Morningstar, Inc |
An expanding and highly qualified team led by one of the industry’s most seasoned investors in the field, combined with a proven process give this fund an edge. The fund’s cheapest share classes receive a Morningstar Analyst Rating of Silver,... | |
Klik her for analytikerens rapport |
Morningstar Søjler | |
---|---|
Team | 24 |
Forening | 23 |
Proces | 24 |
Resultater | |
Omkostninger |
Investeringsmålsætning: Candriam Equities L Biotechnology Class C USD Cap |
The objective of the sub-fund is to use discretionary management to benefit from the performance of the market in global equities of companies from the biotechnology sector, and to outperform the benchmark. This sub-fund may be appropriate for investors who wish to achieve this objective over a long investment holding period and who are aware of, understand and are able to bear the specific risks of the sub-fund as set out below and defined in the section entitled Risk factors in the Prospectus. |
Returns | |||||||||||||
|
Management | ||
Manager navn Startdato | ||
Rudi Van den Eynde 06-04-2000 | ||
Linden Thomson 29-02-2024 | ||
Startdato 06-04-2000 |
Annonce |
Kategoribenchmark | |
Fondens indeks | Morningstar indeks |
NASDAQ Biotechnology TR USD | Morningstar Gbl Biotechnology NR USD |
Target Market | ||||||||||||||||||||
|
Formuefordeling Candriam Equities L Biotechnology Class C USD Cap | 29-02-2024 |
|
|
Top 5 placeringer | Sektor | % |
Vertex Pharmaceuticals Inc | Healthcare | 6,89 |
Regeneron Pharmaceuticals Inc | Healthcare | 6,42 |
Amgen Inc | Healthcare | 5,95 |
Gilead Sciences Inc | Healthcare | 5,74 |
AstraZeneca PLC | Healthcare | 3,64 |
Øget Mindsket Ny siden sidste portefølje | ||
Candriam Equities L Biotechnology Class C USD Cap |